Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications
Industry Supported Symposium
Activity Overview
Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to register for the Personalized Management of Advanced or Recurrent Endomtetrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications Industry Supported Symposium at the IGCS 2024 Annual Global Meeting in Dublin, Ireland.
This course offers an in-depth exploration of personalized treatment approaches for endometrial cancers, focusing on proficient mismatch repair (pMMR), deficient mismatch repair (dMMR) diseases, and molecular classification in the recurrent setting. Through case-based studies, and analysis of clinical data, participants will gain insights into tailored treatment strategies, including the use of immune checkpoint inhibitors, chemotherapy, and targeted therapies. The course also examines the challenges of managing treatment toxicities and poor tolerance in pMMR patients, utilizing evidence from post-adjuvant sub-analyses to inform decision making and optimize patient outcomes.
Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
Upon completion of the activities in this series, learners will demonstrate Increased knowledge regarding:
- Differentiate between pMMR and dMMR endometrial cancers in the recurrent setting, understanding distinct treatment applications and highlighting the importance of MMR testing.
- Analyze real-world case scenarios to determine appropriate treatment sequencing for pMMR patients, incorporating immune checkpoint inhibitors and targeted therapies based on disease progression.
- Evaluate patient responses and adverse event strategies through the discussion of clinical cases, utilizing evidence from post-adjuvant sub analyses.
- Synthesize key learnings and strategies for personalized management of endometrial cancers, understanding disparities for patient populations and emphasizing the importance of optimizing patient care.
Moderator
Dr. Brian Slomovitz
Faculty
Dr. John Chan
Dr. Domenica Lorusso
Dr. Angelica Rodriguez
Agenda
Personalized Management of Advanced or Recurrent Endometrial Cancers:
Navigating pMMR, dMMR Subtypes, or Molecular Classifications,
an Industry Supported Symposium at the IGCS 2024 Annual Global Meeting
In Person on Thursday, October 17, 2024 from 12:30 – 14:00 IST/GMT+1
This session is not included in the main event CME/CPD credit.
All Faculty
John Chan, MD, PhD, California Pacific Medical Center, Sutter Health, San Francisco, California, USA
Angelica Rodriguez, MD, PhD, Federal University of Minas Gerais Minas Gerais, Brazil
All Facutly
Domenica Lorusso, MD, PhD, Humanitas University Milan, Milano, Italy
All Faculty